




PHARMACEUTICAL 2019

Traverse Therapeutics Inc.
Rank 196 of 363





RealRate

PHARMACEUTICAL 2019

Traverse Therapeutics Inc. Rank 196 of 363



The relative strengths and weaknesses of Traverse Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Traverse Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is 81%, being 44% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	495,678
Cost of Goods Sold	5,527
Intangible Assets	187,627
Liabilities, Current	104,621
Liabilities, Non-Current	4,496
Other Assets	22,709
Other Compr. Net Income	-514
Other Expenses	12,159
Other Liabilities	281,790
Other Net Income	-21,827
Other Revenues	164,246
Property and Equipment	3,146
Research and Development	123,757
Selling, General and Administrative Expense	103,654

Output Variable	Value in 1000 USD
Assets	709,160
Liabilities	390,907
Expenses	245,097
Revenues	164,246
Stockholders Equity	318,253
Net Income	-102,678
Comprehensive Net Income	-102,935
Economic Capital Ratio	81%